Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Optical coherence tomography angiography (OCTA)

Method of Measurement (Pre-analytical Tools)
Optical
Biomarker Measured
Vasculature
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

To develop and evaluate biomarkers using non-invasive optical coherence tomography angiography (OCTA) to assess the structure and function of the retinal microvasculature as an effective screening tool in cognitive aging.

Target Population/ Population Being Studied

Patients with MCI and/or AD and controls who are recruited from the relatives/attendants of the patients or will be patients themselves that have not been diagnosed with MCI/AD

Length of Current Trial
12 months
Number of Trial Participants

1000

Estimated Trial Completion
April 2021
What is Required from Patients

noninvasive eye tracking test, noninvasive images of the eye, in clinic visit

What is Required from the Health System

eye tracking device, eye imager, technicians

Sponsor

Duke University

“OCTA in Mild Cognitive Impairment and Alzheimer's Disease.” ClinicalTrials.gov. Accessed October 20, 2019. https://clinicaltrials.gov/ct2/show/NCT03233646?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=10&rank=81